<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947488</url>
  </required_header>
  <id_info>
    <org_study_id>Bioarginina C</org_study_id>
    <nct_id>NCT04947488</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital</brief_title>
  <acronym>BC</acronym>
  <official_title>Evaluation of the Effects of Treatment With Bioarginin C on Physical Exhaustion , Systemic Inflammatory State and Endothelial Function in Adult Subjects Belonging to the Post-Covid Day Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long Covid could be much more frequent than it is thought to be. Few dwell on the great&#xD;
      problem represented by the post covid syndrome. The virus often leaves important marks on our&#xD;
      body, and those who recover face problems of various kinds: chronic fatigue, shortness of&#xD;
      breath, dry cough, headache, cognitive difficulties.&#xD;
&#xD;
      On the duration and resolution of this syndrome, now recognized as a highly debilitating&#xD;
      condition, there are still no great answers: for this reason it is always important to&#xD;
      emphasize that contracting Covid, even in a not serious form, still means exposing oneself to&#xD;
      long-term risks that are still not well codified by the scientific community. Guidelines and&#xD;
      more tools are expected to best assist these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">November 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walking test to evaluate Fatigue</measure>
    <time_frame>30 days</time_frame>
    <description>Effect of Bioarginina C on the prolonged fatigue</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fatigue Syndrome, Chronic</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Bioarginina C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vials based on L-arginine and liposomal vitamin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vials without L-arginine and liposomal vitamin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bioarginina C</intervention_name>
    <description>Dietary supplement vials</description>
    <arm_group_label>Bioarginina C</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        subjects with proven positivity to the molecular test for Sars-cov2 with demonstration of&#xD;
        microbiological healing patients discharged from FPG or other hospital structures; or only&#xD;
        contact in PS; or home management age: range 20-60 years Fatigue operationalized as an&#xD;
        affirmative answer to item &quot;7&quot; (CES-D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pharmacological therapies with possible interactions with the mechanisms / processes under&#xD;
        study (e.g. antihypertensive drugs, cortisone drugs, NSAIDs, immunosuppressants, nitrates)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>barbara maglione</last_name>
    <phone>+393343293357</phone>
    <phone_ext>+393343293357</phone_ext>
    <email>barbara.maglione@farmadamor.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barbara Maglione</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>barbara o maglione</last_name>
      <phone>+393343293357</phone>
      <phone_ext>+393343293357</phone_ext>
      <email>barbara.maglione@farmadamor.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>Matteo Tosato</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

